S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
NASDAQ:MYNZ

Mainz Biomed - MYNZ Stock Forecast, Price & News

$6.25
-0.21 (-3.25%)
(As of 03/28/2023 12:00 AM ET)
Add
Compare
Today's Range
$6.25
▼
$6.53
50-Day Range
$6.11
▼
$7.22
52-Week Range
$5.42
▼
$15.93
Volume
89,441 shs
Average Volume
35,820 shs
Market Capitalization
$75.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

Mainz Biomed MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
172.0% Upside
$17.00 Price Target
Short Interest
Healthy
0.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Mainz Biomed in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.63) to ($1.43) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

349th out of 1,002 stocks

Pharmaceutical Preparations Industry

154th out of 488 stocks

See Top Rated MarketRank™ Stocks Here

MYNZ stock logo

About Mainz Biomed (NASDAQ:MYNZ) Stock

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

Receive MYNZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mainz Biomed and its competitors with MarketBeat's FREE daily newsletter.

MYNZ Stock News Headlines

March 23, 2023 | benzinga.com
Analysts Model Over 74% Upside For Mainz Biomed Stock Ahead Of Key 1/H 2023 Updates ($MYNZ)
March 21, 2023 | finance.yahoo.com
Mainz Biomed to Present at Sidoti Virtual Investor Conference March 22-23
March 28, 2023 | The Oxford Club (Ad)
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
March 15, 2023 | finanznachrichten.de
Mainz BioMed NV: Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany
March 15, 2023 | finance.yahoo.com
Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany
March 8, 2023 | finanznachrichten.de
Mainz BioMed NV: Mainz Biomed Launches Number of Educational Events in Germany to Raise Awareness for CRC Screening and Early Detection
March 8, 2023 | finance.yahoo.com
Mainz Biomed Launches Number of Educational Events in Germany to Raise Awareness for CRC Screening and Early Detection
March 1, 2023 | finance.yahoo.com
Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout “Blue” March 2023
March 28, 2023 | Investor Place Media (Ad)
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
February 28, 2023 | finance.yahoo.com
Mainz Biomed to Appear on ClearThink IR’s Virtual Live Event on Wednesday, March 1, 2023 at 12 Noon ET
February 22, 2023 | msn.com
Mainz stock rises on acquiring IP for colorectal cancer detection test ColoAlert
February 21, 2023 | finance.yahoo.com
Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program
February 15, 2023 | finance.yahoo.com
Mainz Biomed Expands European Commercial Footprint and Enters Markets in Spain and UK
January 18, 2023 | finance.yahoo.com
Mainz Biomed Launches Corporate Health Program in Germany for ColoAlert
January 3, 2023 | finance.yahoo.com
Mainz Biomed Provides Year-End 2022 Corporate Review
December 6, 2022 | finance.yahoo.com
Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study
November 29, 2022 | finance.yahoo.com
Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies
November 22, 2022 | finance.yahoo.com
Mainz Biomed to Participate in Deutsche Eigenkapitalforum and Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
November 15, 2022 | finance.yahoo.com
Mainz Biomed Announces U.S. Extension of ColoFuture Study to Evaluate Integration of Novel mRNA Biomarkers into ColoAlert
November 2, 2022 | finance.yahoo.com
Mainz Biomed Provides Third Quarter 2022 Update
September 28, 2022 | sg.finance.yahoo.com
Mainz Biomed B.V. (4TO.SG)
September 28, 2022 | finance.yahoo.com
Mainz Biomed Strengthens Board of Directors with Nomination of Dr. Heiner Dreismann and Gregory Tibbitts
September 26, 2022 | benzinga.com
Mainz Biomed Targets Multi-Billion Dollar Sales Opportunities With Best-In-Class Cancer Screening Diagnostics ($MYNZ)
September 7, 2022 | finance.yahoo.com
Mainz Biomed Reports First Half 2022 Financial Results
August 23, 2022 | finance.yahoo.com
Mainz Biomed Appoints Dr. D. Kim Turgeon of University of Michigan Health to its Medical Advisory Board
August 17, 2022 | seekingalpha.com
Mainz Biomed stock rises 22% on launch of colorectal cancer test in Italy, UAE
August 16, 2022 | finance.yahoo.com
Mainz Biomed and Dante Genomics Announce Full Commercial Availability of ColoAlert in Italy and the United Arab Emirates
See More Headlines
Receive MYNZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mainz Biomed and its competitors with MarketBeat's FREE daily newsletter.

MYNZ Company Calendar

Today
3/28/2023
Next Earnings (Estimated)
5/01/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MYNZ
CUSIP
N/A
CIK
1874252
Web
mainzbiomed.com
Phone
49-6131-554-2860
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.00
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+165.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.02
Current Ratio
10.83
Quick Ratio
10.82

Sales & Book Value

Annual Sales
$580,000.00
Price / Sales
132.52
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.53 per share
Price / Book
12.08

Miscellaneous

Outstanding Shares
12,010,000
Free Float
N/A
Market Cap
$76.86 million
Optionable
Not Optionable
Beta
0.95

Key Executives

  • Mr. Guido Baechler (Age 58)
    CEO & Director
  • Mr. William J. Caragol (Age 56)
    Chief Financial Officer
  • Mr. Philipp Freese (Age 40)
    Chief Operating Officer
  • Dr. Moritz Eidens Ph.D. (Age 39)
    Chief Science Officer & Director
  • Mr. Darin S. Leigh
    Chief Commercial Officer

Key Competitors

View All Competitors













MYNZ Stock - Frequently Asked Questions

Should I buy or sell Mainz Biomed stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mainz Biomed in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MYNZ shares.
View MYNZ analyst ratings or view top-rated stocks.

What is Mainz Biomed's stock price forecast for 2023?

3 equities research analysts have issued 12 month target prices for Mainz Biomed's stock. Their MYNZ share price forecasts range from $11.00 to $25.00. On average, they expect the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 165.6% from the stock's current price.
View analysts price targets for MYNZ or view top-rated stocks among Wall Street analysts.

How have MYNZ shares performed in 2023?

Mainz Biomed's stock was trading at $7.10 at the beginning of 2023. Since then, MYNZ stock has decreased by 9.9% and is now trading at $6.40.
View the best growth stocks for 2023 here.

Are investors shorting Mainz Biomed?

Mainz Biomed saw a drop in short interest in March. As of March 15th, there was short interest totaling 19,800 shares, a drop of 18.5% from the February 28th total of 24,300 shares. Based on an average trading volume of 29,400 shares, the short-interest ratio is presently 0.7 days. Approximately 0.3% of the shares of the stock are sold short.
View Mainz Biomed's Short Interest.

When is Mainz Biomed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 1st 2023.
View our MYNZ earnings forecast.

When did Mainz Biomed IPO?

(MYNZ) raised $10 million in an initial public offering on Friday, November 5th 2021. The company issued 2,000,000 shares at a price of $4.00-$6.00 per share. Boustead Securities acted as the underwriter for the IPO.

What is Mainz Biomed's stock symbol?

Mainz Biomed trades on the NASDAQ under the ticker symbol "MYNZ."

How do I buy shares of Mainz Biomed?

Shares of MYNZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mainz Biomed's stock price today?

One share of MYNZ stock can currently be purchased for approximately $6.40.

How much money does Mainz Biomed make?

Mainz Biomed (NASDAQ:MYNZ) has a market capitalization of $76.86 million and generates $580,000.00 in revenue each year.

How can I contact Mainz Biomed?

The official website for the company is mainzbiomed.com. The company can be reached via phone at 49-6131-554-2860 or via email at ir@mainz-biomed.com.

This page (NASDAQ:MYNZ) was last updated on 3/28/2023 by MarketBeat.com Staff